Testagen
also known as Lys-Glu-Asp-Gly, KEDG
Short tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson bioregulator tradition, proposed as a testicular tissue-specific regulator. Animal models suggest support for testicular function and spermatogenesis; evidence remains limited to mechanistic and animal studies, with no human clinical trials or regulatory approval. In vitro, the peptide penetrates cell nuclei and shows sequence-specific interaction with deoxyribooligonucleotides and DNA. [fedoreyeva-2011]
- Class
- Bioregulator Peptide
- Evidence level
- Mechanistic animal evidence
- Regulatory status
- Not FDA-approved (US) — research use only
At a glance
SQ · Abdomen · Cyclical
Primary target — Testicular tissue; proposed nuclear DNA interaction.
Pathway — Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis) [fedoreyeva-2011].
Downstream effect — Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interaction [fedoreyeva-2011].
Origin — Khavinson bioregulator school — isolated from testicular tissue peptide fractions.
Feedback intact — Unknown — no HPG axis data.
| Parameter | Value |
|---|---|
| Typical protocol (anecdotal) | 100–200 mcg / dayNo published human dosing studies; derived from Russian bioregulator practice. |
| Frequency | Once daily or alternate days |
| Cycle length | 10–20 days on, 10–14 days offBioregulator tradition uses pulsed cycles; no controlled data. |
| Evidence basis | Animal mechanistic / in vitro only [fedoreyeva-2011] |
| Route | Subcutaneous |
| Reconstitution | Sterile water or bacteriostatic saline |
| Half-life | Unknown — likely minutes (short peptide) |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- — Active testicular malignancy
- — Hormone-sensitive cancers (no data; theoretical caution)
- — Pregnant or breastfeeding (no data)
- 01Reconstitution
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
- 02Injection site
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
- 03Timing
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
- 04Storage
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
- 05Cycle protocol
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.
Frequently asked
Is Testagen FDA-approved?
Testagen is not FDA-approved in the United States and is handled as a research compound (research use only). Regulatory status may differ in other jurisdictions.
Sources
of 41 rendered claims carry a resolvable citation.
- [fedoreyeva-2011]Fedoreyeva 2011 — Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
journal, 2011